BIB - ProShares Ultra Nasdaq Biotechnology
| Previous Close | 63.78 |
| Open | 63.51 |
| Bid | 62.75 x 800 |
| Ask | 64.03 x 800 |
| Day's Range | 62.72 - 64.04 |
| 52 Week Range | 48.12 - 69.62 |
| Volume | 60,108 |
| Avg. Volume | 105,212 |
| Net Assets | 346.02M |
| NAV | 64.08 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 14.18% |
| Beta (3y) | 3.16 |
| Expense Ratio (net) | 0.95% |
| Inception Date | 2010-04-06 |
- Investor's Business Daily•2 months ago
Biotech Funds Tacked On $76 Million This Week — Are They Recovering?
Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon the group hasn't seen in nine months.
Yahoo Finance•7 months agoBayer and J&J win big, Microsoft lags because of Intel, Apple turns over information
Johnson & Johnson, Microsoft, Apple and Toyota are the companies to watch.
- Investor's Business Daily•8 months ago
How Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill
Biotech and pharma stocks dipped after the Senate's GOP tax reform leaves the fate of a key tax credit up in the air.
- ETF Trends•11 months ago
Biotech, Pharma ETFs Leave Pricing Drama Behind
Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...
- ETF Trends•11 months ago
Biotech ETF Investing is Hot, Can Get Hotter
Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...
- Yahoo Finance•last year
Why $475,000 isn't actually that expensive for Novartis's new drug
The price tag on Novartis' new cancer drug may be a bargain
- ETF Trends•last year
Biotech ETF Investing is Starting to Look Good – Here’s Why
The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...
- Market Realist•last year
Must-Know Developments for Ionis Pharmaceuticals
Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.
